| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22639 | RWJ-49815 | A potent bactericidal agent that inhibits the KinA autophosphorylation with IC50 of 1.6 uM. |
|
| DC23289 | BCL6 inhibitor 7 | A potent BCL6 protein-protein interaction inhibitor with Kd of 78 nM. |
|
| DC23212 | DMCM hydrochloride | A potent benzodiazepine inverse agonist that displays anxiogenic and potent convulsant activity. |
|
| DC11568 | HJB-97 | A potent BET bromodomian inhibitor with IC50 of 3-7 nM for BRD2/3/4 BD1 and BD2.. |
|
| DC22443 | Paxilline Featured | A potent blocker of high-conductance Ca2+-activated K+ (BKCa, KCa1.1) channels that binds to the α-subunit of BKCa with Ki of 1.9 nM. |
|
| DC21833 | DMP 543 Featured | A potent blocker of voltage-gated potassium channels Kv7 (KCNQ) that enhances ACh release from rat hippocampal slices in vitro with EC50 of 0.7 uM. |
_1.png)
|
| DC21621 | Ronacaleret hydrochloride | A potent calcium sensing receptor (CaSR) negative allosteric modulator with IC50 of 146 nM for hCaSR. |
|
| DC21622 | Ronacaleret | A potent calcium sensing receptor (CaSR) negative allosteric modulator with IC50 of 146 nM for hCaSR. |
|
| DC22641 | NWL-117 | A potent Caspase-6 inhibitor with IC50 of 192 nM, also inhibits Caspase-4/8/9/10 with IC50 of 0.1-0.8 uM. |
|
| DC24000 | MK-0812 succinate | A potent CCR2 specific antagonist that blocks MCP-1 mediated response with an IC50 of 3.2 nM. |
|
| DC23536 | AF-399 42016530 | A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo. |
|
| DC23535 | ST 016907 | A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.. |
|
| DC22649 | NU-6102 | A potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively. |
|
| DC11625 | Divin | A potent chelator of iron that arrests late stages of cytokinesis by blocking the physical process of constriction in dividing cells. |
|
| DC11699 | VUF11403 | A potent CXCR7 (ACKR3) agonist.. |
|
| DC22965 | R-116010 | A potent CYP26A1 inhibitor with IC50 of 10 nM, potently inhibits all-trans-retinoic acid metabolism in intact T47D cells with IC50 of 8.7 nM. |
|
| DC23905 | Beaucage reagent Featured | Beaucage reagent is a DNA cleavage reagent. |
|
| DC22389 | Metoclopramide | A potent dopamine D2 receptor antagonist with Ki of 28 nM. |
|
| DC22390 | Metoclopramide hydrochloride hydrate | A potent dopamine D2 receptor antagonist with Ki of 28 nM. |
|
| DC22908 | OSU-6162 hydrochloride | A potent dopamine stabilizer with Ki of 447 and 1305 nM for D2 and D3 receptors respectively. |
|
| DC22438 | Burimamide | A potent dual H3/H2 receptor antagonist with Ki of 0.07 and 7.8 uM, respectively. |
|
| DC23948 | AV-412 | A potent dual inhibitor of EGFR and ErbB2. |
|
| DC22652 | CBP-93872 | A potent G2 checkpoint inhibitor that specifically abrogates the DNA double-stranded break (DSB)-induced G2 checkpoint. |
|
| DC22958 | RU-GIRK-1 | A potent GIRK2 inhibitor that inhibits GIRK2-mediated flux with an IC50 of 0.35 uM. |
|
| DC22884 | PF-06372222 | A potent glucagon receptor (GCGR) negative allosteric modulator.. |
|
| DC11797 | PBD-150 Featured | A potent glutaminyl cyclase (QC) inhibitor with Ki of 60 nM. |
|
| DC23947 | Indirubin-3'-monoxime Featured | A potent GSK3β inhibitor with IC50 of 22 nM. |
|
| DC23702 | AM-9514 | A potent gucokinase (GK) activator with EC50 of 0.29 uM. |
|
| DC23991 | Daclatasvir Featured | Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. Nevertheless, and for unknown reasons, successful all-oral regimens of antiviral therapy in patients with chronic hepatitis C and cirrhosis is occasionally complicated by hepatic decompensation and may cause reactivation of hepatitis B in susceptible patients coinfected with the hepatitis B virus (HBV). |
.gif)
|
| DC23957 | RO-9187 | A potent HCV NS5B RNA polymerase inhibitor. |
|
